Endometrial cancer molecular risk stratification is equally prognostic for endometrioid ovarian carcinoma
…, HP Sinn, S Heublein, F Kommoss, HW Vollert… - Clinical Cancer …, 2020 - AACR
Purpose: Endometrioid ovarian carcinoma (ENOC) is generally associated with a more
favorable prognosis compared with other ovarian carcinomas. Nonetheless, current patient …
favorable prognosis compared with other ovarian carcinomas. Nonetheless, current patient …
Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in …
…, J Boros, F Kommoss, HW Vollert… - The Journal of …, 2022 - Wiley Online Library
ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an
important tumour suppressor role, and is considered prognostic in several malignancies. …
important tumour suppressor role, and is considered prognostic in several malignancies. …
Interest in integrative medicine among postmenopausal hormone receptor–positive breast cancer patients in the EvAluate-TM Study
…, N Fersis, T Kuhn, C Wolf, HW Vollert… - Integrative cancer …, 2017 - journals.sagepub.com
Background. Breast cancer patients often use complementary and alternative medicine, but
few prospectively collected data on the topic are available specifically for postmenopausal …
few prospectively collected data on the topic are available specifically for postmenopausal …
[HTML][HTML] Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the …
…, JW Siebers, M Popovic, T Kuhn, C Wolf, HW Vollert… - BMC cancer, 2019 - Springer
Background Treatment of postmenopausal, hormone receptor-positive metastatic breast cancer
(MBC) patients varies despite clear therapy guidelines, favoring endocrine treatment (ET)…
(MBC) patients varies despite clear therapy guidelines, favoring endocrine treatment (ET)…
Prognostic and immunological significance of ARID1A status in endometriosis-associated ovarian Carcinoma
…, CJ Kennedy, J Boros, F Kommoss, HW Vollert… - MedRxiv, 2021 - medrxiv.org
ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an
important tumor suppressor role, and is considered prognostic in several malignancies. …
important tumor suppressor role, and is considered prognostic in several malignancies. …
Factors influencing decision-making for or against adjuvant and neoadjuvant chemotherapy in postmenopausal hormone receptor-positive breast Cancer patients in …
…, JW Siebers, N Fersis, T Kuhn, C Wolf, HW Vollert… - Breast Care, 2016 - karger.com
Background: Decision-making for or against neoadjuvant or adjuvant chemotherapy in
postmenopausal patients with hormone receptor-positive breast cancer does not follow any clear …
postmenopausal patients with hormone receptor-positive breast cancer does not follow any clear …
[HTML][HTML] Diagnostic and Clinical Value of Doppler Sonography of the Uterine Arteries at 20-23 Weeks of Gestation in a Low Risk Population
HW Vollert - 2001 - refubium.fu-berlin.de
Objective: To identify the definition of pathological waveform which optimises the diagnostic
value of Doppler sonography of the uterine arteries (DSUA) at 20-23 gestational weeks as a …
value of Doppler sonography of the uterine arteries (DSUA) at 20-23 gestational weeks as a …
[CITATION][C] PharmaNews
…, JW Siebers, N Fersis, T Kuhn, C Wolf, HW Vollert… - Breast Care, 2016 - karger.com
MammaTyper® erlaubt die präzise quantitative Bestimmung der mRNAExpression der Biomarker
ERBB2 (HER2), ESR1 (ER), PGR (PR) und MKI67 (Proliferationsmarker Ki-67), die die …
ERBB2 (HER2), ESR1 (ER), PGR (PR) und MKI67 (Proliferationsmarker Ki-67), die die …
[CITATION][C] Meetings and Conferences
…, JW Siebers, N Fersis, T Kuhn, C Wolf, HW Vollert… - Breast Care, 2016 - karger.com
Meetings and Conferences Page 1 © 2016 S. Karger GmbH, Freiburg Accessible online at:
www.karger.com/brc Fax +49 761 4 52 07 14 Information@Karger.com www.karger.com …
www.karger.com/brc Fax +49 761 4 52 07 14 Information@Karger.com www.karger.com …
Self-reported improvement in side effects and quality of life with integrative medicine in breast cancer patients
CC Hack, J Hackl, NBM Hüttner… - Integrative cancer …, 2018 - journals.sagepub.com
Purpose. Although the demand from patients for integrative medicine is increasing, complementary
medicine services are still quite heterogeneous and have not been incorporated into …
medicine services are still quite heterogeneous and have not been incorporated into …
